MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

Company Performance - MaxCyte, Inc. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, and compared to a loss of $0.09 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $8.51 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 14.93%, and down from $10.43 million in the same quarter last year [2] - Over the last four quarters, MaxCyte has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - MaxCyte shares have lost approximately 50.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for MaxCyte is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.09 on revenues of $10.4 million, and for the current fiscal year, it is -$0.38 on revenues of $41.2 million [7] - The estimate revisions trend for MaxCyte was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - MaxCyte operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [8]